The association between reduced downstream antioxidant effects due to decreased NRF2 activity, evident with age and in age-related cataracts, has garnered attention for NRF2 as a therapeutic target for cataract treatment and prevention [96]. This evidence concerns the gene NFE2L2 and Age-related cataract.